[HTML][HTML] Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
H Wang, G Kaur, AI Sankin, F Chen, F Guan… - Journal of hematology & …, 2019 - Springer
Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …
[HTML][HTML] Update on PD-1/PD-L1 inhibitors in multiple myeloma
T Jelinek, B Paiva, R Hajek - Frontiers in immunology, 2018 - frontiersin.org
The treatment of cancer, especially of various types of solid tumors, has been revolutionized
by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success …
by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success …
[HTML][HTML] Checkpoint inhibition in myeloma: opportunities and challenges
F Costa, R Das, J Kini Bailur, K Dhodapkar… - Frontiers in …, 2018 - frontiersin.org
Despite major improvements in the treatment landscape, most multiple myeloma (MM)
patients eventually succumb to the underlying malignancy. Immunotherapy represents an …
patients eventually succumb to the underlying malignancy. Immunotherapy represents an …
[HTML][HTML] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
R Tremblay-LeMay, N Rastgoo, H Chang - Journal of hematology & …, 2018 - Springer
Even with recent advances in therapy regimen, multiple myeloma patients commonly
develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has …
develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has …
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
IS Okoye, L Xu, J Walker, S Elahi - Cancer Immunology, Immunotherapy, 2020 - Springer
On-treatment steroids for countering immune checkpoint inhibitor-induced inflammatory
responses (irAEs) are a hallmark of cancer immunotherapy. However, the suppressive …
responses (irAEs) are a hallmark of cancer immunotherapy. However, the suppressive …
Immune checkpoint inhibitors in multiple myeloma: A review of the literature
The human immune system has structures called checkpoints controlling the intensity and
the duration of immune responses. In the last years, studies and research have been …
the duration of immune responses. In the last years, studies and research have been …
[HTML][HTML] Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on minimal residual disease and immune profiling
SA Holstein, JC Ye, A Howard, M Bhutani… - Biology of Blood and …, 2019 - Elsevier
The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was …
Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was …
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma
A Oriol - Expert Review of Hematology, 2020 - Taylor & Francis
Introduction Several modalities of immunotherapy have proved successful in multiple
myeloma, including immunomodulatory agents, monoclonal antibodies directed to plasma …
myeloma, including immunomodulatory agents, monoclonal antibodies directed to plasma …